Journal of pediatric hematology/oncology
September 7, 2026 · via Europe PMC
Audiological Outcomes Following Platinum-Based Chemotherapy in Pediatric Oncology Patients.
Orhan MF, Tiryaki Ö, Kudubeş AA, Zengin H, Delibaş K
AI summary — for doctors, generated from the abstract only
In a small cohort of children receiving platinum-based chemotherapy, most developed measurable high-frequency hearing loss, supporting the importance of routine audiological monitoring.
What was studied
A retrospective study of 14 pediatric oncology patients (ages 1 month to 18 years) who received platinum-based chemotherapy between 2015 and 2023 and had both pre- and post-treatment audiometric evaluations (250-6000 Hz), with hearing loss classified according to American Speech-Language-Hearing Association criteria.
Key findings
- Hearing thresholds generally increased after treatment, with the greatest increase and a large effect size seen at high frequencies (4,000-6,000 Hz).
- 85.7% of patients had high-frequency hearing loss on post-treatment assessment.
- The increase in hearing thresholds was significantly greater at high frequencies than at low frequencies; a trend toward greater hearing loss in the left ear compared with the right was observed but was not statistically significant.
Clinical relevance
The findings support regular audiological monitoring, particularly of high-frequency hearing, in children receiving platinum-based chemotherapy, to allow early identification and management of ototoxicity-related hearing loss.
Who should care
Limitations
This was a very small, single-center retrospective study (14 patients) without a comparison group, which limits the precision and generalizability of the findings, though the use of paired pre- and post-treatment measurements in the same patients strengthens the association.
Most children in this small cohort developed high-frequency hearing loss after platinum-based chemotherapy, underscoring the value of routine hearing monitoring.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
PURPOSE
This study aimed to retrospectively evaluate the audiological monitoring of ototoxicity developing in pediatric oncology patients receiving platinum-based chemotherapy.
METHODS
This retrospective study included 14 patients aged 1 month to 18 years who received platinum-based chemotherapy at the pediatric hematology/oncology clinic between 2015 and 2023 and had pre- and post-treatment audiometric evaluations. Audiometric evaluations were performed in the 250 to 6000 Hz frequency range, and hearing loss was classified according to American Speech-Language-Hearing Association criteria.
RESULTS
A general increase in hearing thresholds was observed post-treatment, with the magnitude varying by frequency. While significant changes were detected in low and midfrequencies, the most pronounced increase was observed in high frequencies (4000 to 6000 Hz), and the effect size was large at these frequencies. In the assessment of high-frequency hearing loss, 85.7% of patients had hearing loss. When comparing low and high frequencies, the increase in hearing thresholds was significantly greater at high frequencies. In comparisons between the right and left ears, a tendency toward greater hearing loss was observed in the left ear; however, this difference was not statistically significant.
CONCLUSION
Platinum-based chemotherapy may be associated with clinically relevant hearing threshold shifts in pediatric oncology patients, particularly at high frequencies. Regular audiological monitoring is important for the early identification and management of hearing loss.
DOI
10.1097/mph.0000000000003270
PMID
42704306
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed